US Stock MarketDetailed Quotes
PTN Palatin Technologies
- 2.2900
- -0.0600-2.55%
Close May 10 16:00 ET
36.95MMarket Cap-768P/E (TTM)
2.4700High2.2101Low228.88KVolume2.4200Open2.3500Pre Close534.20KTurnover1.47%Turnover RatioLossP/E (Static)16.14MShares5.650052wk High-3.24P/B35.59MFloat Cap1.430052wk Low--Dividend TTM15.54MShs Float2687.5000Historical High--Div YieldTTM11.06%Amplitude1.4300Historical Low2.3340Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Palatin Technologies Stock Forum
Palatin Technologies, Inc. (NYSE American: PTN), a pioneering biopharmaceutical company, has recently made a significant stride in the treatment of obesity by gaining FDA clearance for its Investigational New Drug (IND) application. This clearance allows Palatin to proceed with a Phase 2 clinical study e...
Palatin Announces FDA Clearance of Ind Application for the Co-Administration of Bremelanotide With Tirzepatide (GLP-1) for the Treatment of Obesity
NEWS
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
NEWS
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
In a significant development for millions suffering from Dry Eye Disease (DED), Palatin Technologies, Inc. recently unveiled the results of their Phase 3 PL9643 MELODY-1 clinical trial at the prestigious American Society of Cataract and Refractive Surgery (ASCRS) conference in 2024. The findings mark a promising advancement...
$Palatin Technologies(PTN.US)$ this company is huge opportunity it has massive funding with 6B USD it’s go to the top 100% sure.
my advice is buy
the $Palatin Technologies(PTN.US)$ will go to the point because it has 6B USD funding
now buy this is moment
Palatin Technologies, Inc. announced positive Phase 3 trial results for PL9643, a potential treatment for dry eye disease (DED), presented by Dr. Eric Donnenfeld at the American Society of Cataract and Refractive Surgery Conference.
The study showed statistically significant improvement in pain and multiple seco...
Benzinga· 2 mins ago
No comment yet